Cargando…

Evidence for a second ankylosing spondylitis-associated RUNX3 regulatory polymorphism

OBJECTIVES: To explore the functions of RUNX3 single nucleotide polymorphisms (SNPs) associated with ankylosing spondylitis (AS). METHODS: Individual SNP associations were evaluated in 4230 UK cases. Their effects on transcription factor (TF) binding, transcription regulation, chromatin modification...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vecellio, Matteo, Cortes, Adrian, Roberts, Amity R, Ellis, Jonathan, Cohen, Carla Jayne, Knight, Julian C, Brown, Matthew A, Bowness, Paul, Wordsworth, Bryan Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845418/ https://www.ncbi.nlm.nih.gov/pubmed/29531791 http://dx.doi.org/10.1136/rmdopen-2017-000628

Ejemplares similares

Functional Genomic Analysis of a RUNX3 Polymorphism Associated With Ankylosing Spondylitis
por: Vecellio, Matteo, et al.
Publicado: (2021)

The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression
por: Vecellio, Matteo, et al.
Publicado: (2016)

RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?
por: Vecellio, Matteo, et al.
Publicado: (2019)

Disruption of c-MYC Binding and Chromosomal Looping Involving Genetic Variants Associated With Ankylosing Spondylitis Upstream of the RUNX3 Promoter
por: Cohen, Carla J., et al.
Publicado: (2022)

An ankylosing spondylitis-associated genetic variant in the IL23R-IL12RB2 intergenic region modulates enhancer activity and is associated with increased Th1-cell differentiation
por: Roberts, Amity R, et al.
Publicado: (2016)

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
por: Li, Zhixiu, et al.
Publicado: (2021)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis
por: Nam, Bora, et al.
Publicado: (2023)

Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades
por: Crossfield, Samantha S R, et al.
Publicado: (2021)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Ankylosing spondylitis and mortality following hospitalised pneumonia: a population-based cohort study
por: Holland-Fischer, Mette, et al.
Publicado: (2020)

Perspectives on the Genetic Associations of Ankylosing Spondylitis
por: Wordsworth, B. Paul, et al.
Publicado: (2021)

Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity
por: van Genderen, Simon, et al.
Publicado: (2016)

Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012
por: Huscher, Dörte, et al.
Publicado: (2015)

Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis
por: Maneiro, Jose Ramon, et al.
Publicado: (2015)

Non-classical human leucocyte antigens in ankylosing spondylitis: possible association with HLA-E and HLA-F
por: Santos, Margarida Rodrigues, et al.
Publicado: (2018)

Relationship between the gut and the spine: a pilot study of first-degree relatives of patients with ankylosing spondylitis
por: Kehl, Amy S, et al.
Publicado: (2017)

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
por: Deodhar, Atul, et al.
Publicado: (2021)

Chromosome conformation capture approaches to investigate 3D genome architecture in Ankylosing Spondylitis
por: Davidson, Connor, et al.
Publicado: (2023)

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
por: Marzo‐Ortega, H., et al.
Publicado: (2017)

Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors
por: Essers, Ivette, et al.
Publicado: (2015)

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
por: Baraliakos, X, et al.
Publicado: (2016)

Association of childhood infections and perinatal factors with ankylosing spondylitis: a Swedish nationwide case–control and sibling study
por: Morin, Matilda, et al.
Publicado: (2023)

Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis
por: Ramiro, Sofia, et al.
Publicado: (2015)

Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study
por: Webers, Casper, et al.
Publicado: (2018)

Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study
por: Bengtsson, Karin, et al.
Publicado: (2019)

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
por: Marzo-Ortega, Helena, et al.
Publicado: (2017)

Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
por: Deodhar, Atul A., et al.
Publicado: (2016)

Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort
por: Rubio Vargas, Roxana, et al.
Publicado: (2016)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022)

Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry
por: Michelena, Xabier, et al.
Publicado: (2022)

Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross‐Sectional Study
por: Fernández‐Carballido, Cristina, et al.
Publicado: (2020)

Risk factors for progression of juvenile-onset non-radiographic axial spondyloarthritis to juvenile-onset ankylosing spondylitis: a nested case–control study
por: Li, Hao-Guang, et al.
Publicado: (2021)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Occurrence and relative risks for non-vertebral fractures in patients with ankylosing spondylitis compared with the general population: a register-based study from Sweden
por: Bengtsson, Karin, et al.
Publicado: (2023)

Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis
por: Cauli, Alberto, et al.
Publicado: (2018)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study
por: Lindström, Ulf, et al.
Publicado: (2018)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5245mdn775pv06k5clnqu8qfl1